A regulatory decision arriving this summer could be very good news if you’re interested in peptide therapy. On July 23–24, 2026, an FDA advisory committee will review seven popular peptides for approval through compounding pharmacies. If the review goes favorably and these are cleared, it would open the door to safer, simpler, physician-guided access to therapies that many people have wanted for years. Here’s what that would mean for you.
What’s being decided
The FDA’s Pharmacy Compounding Advisory Committee (PCAC) will consider adding seven peptides to the 503A Bulks List — the official list of ingredients that pharmacies are allowed to use when preparing customized medications. Under review are BPC-157, KPV, TB-500, and MOTS-c (July 23), plus Emideltide/DSIP, Semax, and Epitalon (July 24). A second round of five more peptides is expected by early 2027.
The benefits if everything is approved
Legitimate, regulated access. Today, people who want these peptides often turn to unregulated “research chemical” sources of unknown origin. If approved, you could obtain them legally and straightforwardly — through a prescription, filled by a licensed pharmacy, as part of your care here.
Quality and safety you can trust.
Compounded medications from licensed pharmacies are made from properly sourced, tested ingredients under real pharmacy standards. That’s a world apart from gray-market products that can carry impurities, inconsistent potency, or contamination. Approval means knowing exactly what you’re putting in your body.
A protocol built around you.
A prescription pathway puts your physician at the center — choosing the right peptide, dialing in the dose, and monitoring how you respond over time, rather than you guessing on your own.
Support for the goals you already care about. The peptides under review are being evaluated across areas like tissue repair and recovery, gut and inflammatory health, sleep, cognitive support, and metabolic health — many of the same goals our patients bring to us every day.
What to keep in mind
This is a pathway to compounded access, not full FDA drug approval, so these would remain prescription therapies used under medical supervision. And while a favorable vote is encouraging, the FDA still finalizes the process afterward, so timing may unfold over the coming months. The takeaway: the door is opening, and we want you positioned to walk through it safely.
We’re ready when you are
We’re tracking the July decision closely and preparing so that, if these peptides are approved, we can offer them to you quickly, safely, and through trusted sources. If peptide therapy is on your radar, let’s talk about whether it fits your goals and health history.